Faculty profile

Michael Kolinsky

ResearcherOncologyUniversity of Alberta

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a University of Alberta directory, so their courses and email address may be missing. Find their university profile.

Michael Kolinsky

Researcher

Oncology

Health Sciences

University of Alberta

Edmonton, Alberta, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
10 publications in the last five years, latest in 2026.
Senior (last) author on 2 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2023.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Dna Damage Response (Ddr) Genes Economics Genomic Testing Metastatic Castration-Resistant Prostate Cancer Patient-Reported Outcomes Personalized Medicine Platinum Chemotherapy Quality Of Life

Latest papers

Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.
Current oncology (Toronto, Ont.) · 2026
Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
18F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.
Advances in urology · 2026

All 19 publications

Latest funding

oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes
CIHR · 2023 · Nominated PI
$1,828,350

All 1 grants and awards

19 publications.

Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.

Sayed S, Kumar R, Zarba M, Mahsin M, Taleb A, Alshammari L, Mairs S, Basappa N, Kolinsky M, Mahoney M, Navani V, Cheng T, Karim S, Lee-Ying R, Yip S, Heng DYC, North S, Alimohamed N

Current oncology (Toronto, Ont.)2026

DOI: 10.3390/curroncol33090542 PMID: 42782889

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

Jordan SE, González-Martin A, Morlock R, Hubig L, Yonemori K, Eberst L, Zikan M, Kim HS, Banerjee S, Damian F, Salutari V, Henry S, Raimondo M, Kolinsky M, Woelber L, Tromp J, Hietanen S, Nishio S, Lee JY, Manso L, Cruz F, Barraclough L, Oaknin A, Van Nieuwenhuysen E, Randall L, Lo SH, Mutebi A, Abrahami D, Leary A, Vergote I

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2026

DOI: 10.1016/j.ijgc.2026.104947 PMID: 42680635

18F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.

Stanton Z, Woloschuk B, Tamm A, Hung R, Trivedi A, Kolinsky M, Usmani N, Rowe L, Moore R, Wuest F, Abele J

Advances in urology2026

DOI: 10.1155/aiu/8550174 PMID: 42440684

Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.

Jovel J, Polzer B, Patterson J, Yong H, Vasquez C, O'keefe S, Pink D, Li G, Fairey A, Adam B, Teitelbaum J, Salimi A, Kirsh S, Alberter B, Lowes L, Carpenter E, Kolinsky M, Zhu Z, Zhou Q, Venner P, Venner C, Williams D, Allan A, Boutros PC, Klein CA, Wong G, Lewis JD

BMC genomic data2026

DOI: 10.1186/s12863-026-01435-5 PMID: 42098607

Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning-assisted opportunistic quantitative computed tomography.

Matheson BE, Jaremko JL, Dowhanik A, Gill J, Gallant C, Walker J, Armani N, Leslie WD, Kolinsky M, Boyd SK, Ye C

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research2025

DOI: 10.1093/jbmr/zjaf009 PMID: 39849845

Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.

Robin G, Basappa NS, North S, Ghosh S, Kolinsky M

Current oncology (Toronto, Ont.)2024Senior author

DOI: 10.3390/curroncol31090375 PMID: 39330003

2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium: Meeting highlights

Graham J, Fallah-Rad N, Kolinsky M, Morgan S, Shayegan B

Journal of the Canadian Urological Association2024Open Access

DOI: 10.5489/cuaj.8797 PMID: W4395695140

Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event.

Ye C, Lee K, Leslie WD, Lin M, Walker J, Kolinsky M

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2023Senior author

DOI: 10.1007/s00198-023-06690-1 PMID: 36729143

Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.

Kiciak A, Clark W, Uhlich M, Letendre A, Littlechild R, Lightning P, Vasquez C, Singh R, Broomfield S, Martin AM, Huang G, Fairey A, Kolinsky M, Wallis CJD, Fung C, Hyndman E, Yip S, Bismar TA, Lewis J, Ghosh S, Kinnaird A

Cancer2023

DOI: 10.1002/cncr.34812 PMID: 37424308

2023 Canadian Urological Association guideline: Genetic testing in prostate cancer

Rendon RA, Selvarajah S, Wyatt AW, Kolinsky M, Schrader KA, Fleshner NE, Kinnaird A, Merrimen J, Niazi T, Saad F

Journal of the Canadian Urological Association202317 citationsOpen Access

DOI: 10.5489/cuaj.8588 PMID: W4387341485

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2023

Subject: Prospective PhD student: Dna Damage Response (Ddr) Genes Dear Professor Kolinsky, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes" (2023), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Michael Kolinsky

Research

Latest papers

Latest funding

Toxicity, Dose Intensity, and Clinical Outcomes with First-Line Enfortumab Vedotin Plus Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.

Patient-reported outcomes with tisotumab vedotin versus chemotherapy in patients with recurrent or metastatic cervical cancer: post hoc analyses from the open-label, randomized, phase 3 ENGOT-cx12/GOG-3057/innovaTV 301 trial.

18F-PSMA-1007 PET/CT Demonstrates Higher Accuracy for Biochemically Recurrent Prostate Cancer Compared to Contemporary Conventional Imaging.

Single-cell genomic analysis of cancer cells from one treatment-na&#xef;ve patient with metastatic prostate cancer.

Assessing the effects of immune checkpoint inhibitors on bone utilizing machine learning-assisted opportunistic quantitative computed tomography.

Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.

2024 American Society of Clinical Oncology Genitourinary (ASCO-GU) Cancers Symposium: Meeting highlights

Fracture rate increases after immune checkpoint inhibitor treatment: a potential new immune related adverse event.

Disparities in prostate cancer screening, diagnoses, management, and outcomes between Indigenous and non-Indigenous men in a universal health care system.

2023 Canadian Urological Association guideline: Genetic testing in prostate cancer

oPTion-DDR: A randomized phase III trial investigating Platinum and Taxane chemotherapy in metastatic castration resistant prostate cancer patients with alterations in DNA Damage Response (DDR) genes

Frequent collaborators

Bobby Shayegan

Christina Canil

Carrie Ye

Michael Ong

Sebastien Hotte

Antonio Finelli

Nawaid Usmani

Aly-Khan Lalani

Libni Eapen

Krista Noonan

Scott Morgan

Randy Littlechild

Cassandra Gallant

Ronald Moore

Srikala Sridhar

Peter Black

Christopher Venner

Jean-Mathieu Beauregard

Som Mukherjee

Kim Chi

Frank Wuest

Neil Fleshner

Wassim Kassouf

John Lewis

Alison Allan

Eric Winquist

Piotr Czaykowski

Ilias Cagiannos

Single-cell genomic analysis of cancer cells from one treatment-naïve patient with metastatic prostate cancer.